Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.41 CAD
Change Today +0.01 / 2.50%
Volume 29.0K
TPI On Other Exchanges
Symbol
Exchange
OTC US
Munich
As of 1:23 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

t-bird pharma inc (TPI) Snapshot

Open
C$0.40
Previous Close
C$0.40
Day High
C$0.41
Day Low
C$0.37
52 Week High
09/9/14 - C$0.95
52 Week Low
01/29/15 - C$0.35
Market Cap
18.9M
Average Volume 10 Days
21.7K
EPS TTM
--
Shares Outstanding
46.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for T-BIRD PHARMA INC (TPI)

Related News

No related news articles were found.

t-bird pharma inc (TPI) Related Businessweek News

No Related Businessweek News Found

t-bird pharma inc (TPI) Details

T-Bird Pharma Inc. operates as a pharmaceutical company in Canada. It primarily focuses on developing medical marijuana products. The company is based in White City, Canada.

t-bird pharma inc (TPI) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: C$12.5K
Corporate Secretary, Director and Member of C...
Total Annual Compensation: C$93.3K
Compensation as of Fiscal Year 2014.

t-bird pharma inc (TPI) Key Developments

T-Bird Pharma Inc. Announces Board Changes

T-Bird Pharma Inc. announced the founder and Chairman of Medna, Dr. Avtar Dhillon, has joined the board of the company as Chairman along with Jim Heppell, Director of Medna, and Punit Dhillon, currently CEO of OncoSec Medical. David Raffa will continue as a director of the company but will step down as Chairman in favor of Dr. Dhillon. In conjunction with the closing Frank Barr, Dr. Essam Hamza and Dr. Bin Huang have resigned from the board. Dr. Huang will remain as CEO of the company.

T-Bird Pharma Inc. Announces Health Canada Submission for Second Production Facility

T-Bird Pharma Inc. announced that it has submitted an application to Health Canada for a second medical marijuana production facility in Victoria, BC. The leased facility has 28,966 square feet of floor space with the option to add approximately 14,500 square feet of mezzanine space for a total of approximately 43,500 square feet and when fully built out will have an annual production capacity in excess of 2,000 kilograms. Building permits for the leasehold upgrades required to the facility have been obtained from the City of Victoria and the current municipal zoning allows for a medical marijuana production facility.

T-Bird Pharma Inc. Announces Management Changes

The founder and Chairman of Medna and its largest shareholder, Dr. Avtar Dhillon, will join the Board of T-Bird as Chairman on the closing of the Escrow Transfer. Joining him on the Board of T-Bird will be Jim Heppell, CEO of Medna, and Punit Dhillon, currently CEO of OncoSec Medical. Stepping down from the Board of T-Bird will be Frank Barr, Dr. Essam Hamza and Dr. Bin Huang. David Raffa will continue as a director of T-Bird but will step down as Chairman in favour of Dr. Dhillon. Dr. Huang will maintain her role as CEO of T-Bird. Dr. Dhillon served as President and CEO of Inovio Pharmaceuticals from October 2001 to June 2009, as President and Chairman of Inovio from June 2009 until October 2009, as Executive Chairman until August 2011, and as Chairman from September 2011. During his tenure at Inovio, Dr. Dhillon led the successful turnaround of the company through a restructuring, acquisition of technology from several European and North American companies, and a merger with VGX Pharmaceuticals to develop a vertically integrated DNA vaccine development company. Dr. Dhillon led multiple successful financings for Inovio, raising over $200 million for the company, and concluded several licensing deals that included multinational companies, Merck and Wyeth (now Pfizer). Dr. Dhillon has served as Chairman of the Board of OncoSec since March 2011 and of Arch Therapeutics since April 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TPI:CN C$0.41 CAD +0.01

TPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TPI.
View Industry Companies
 

Industry Analysis

TPI

Industry Average

Valuation TPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 14.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact T-BIRD PHARMA INC, please visit www.tbirdpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.